Prospects and perils of ChatGPT in diabetes

Abstract

ChatGPT, a popular large language model developed by OpenAI, has the potential to transform the management of diabetes mellitus. It is a conversational artificial intelligence model trained on extensive datasets, although not specifically health-related. The development and core components of ChatGPT include neural networks and machine learning. Since the current model is not yet developed on diabetes-related datasets, it has limitations such as the risk of inaccuracies and the need for human supervision. Nevertheless, it has the potential to aid in patient engagement, medical education, and clinical decision support. In diabetes management, it can contribute to patient education, personalized dietary guidelines, and providing emotional support. Specifically, it is being tested in clinical scenarios such as assessment of obesity, screening for diabetic retinopathy, and provision of guidelines for the management of diabetic ketoacidosis. Ethical and legal considerations are essential before ChatGPT can be integrated into healthcare. Potential concerns relate to data privacy, accuracy of responses, and maintenance of the patient-doctor relationship. Ultimately, while ChatGPT and large language models hold immense potential to revolutionize diabetes care, one needs to weigh their limitations, ethical implications, and the need for human supervision. The integration promises a future of proactive, personalized, and patient-centric care in diabetes management.

Ähnliche Arbeiten